Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reissued a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $63.40.

Catalent Price Performance

Shares of NYSE:CTLT opened at $63.48 on Friday. The firm has a market capitalization of $11.52 billion, a PE ratio of -28.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. Catalent has a 52-week low of $41.15 and a 52-week high of $63.50. The firm has a fifty day moving average of $61.27 and a 200 day moving average of $59.87.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.10) earnings per share. As a group, research analysts anticipate that Catalent will post 0.78 EPS for the current fiscal year.

Insider Transactions at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Brooklyn Investment Group bought a new stake in shares of Catalent during the third quarter valued at approximately $31,000. Sentry Investment Management LLC purchased a new position in shares of Catalent in the third quarter worth $53,000. Longfellow Investment Management Co. LLC lifted its holdings in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its position in shares of Catalent by 57.5% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock valued at $72,000 after buying an additional 431 shares during the last quarter. Finally, Intact Investment Management Inc. bought a new stake in Catalent in the 3rd quarter worth about $73,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.